FV100 as a new approach for the possible treatment of varicella-zoster virus infection | Zendy

Christopher McGuigan | Zendy; Jan Balzarini | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

FV100 as a new approach for the possible treatment of varicella-zoster virus infection

Author(s) -

Christopher McGuigan,

Jan Balzarini

Publication year - 2009

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkp294

Subject(s) - varicella zoster virus , shingles , virus , virology , potency , lipophilicity , clinical trial , medicine , drug , biology , pharmacology , in vitro , genetics , biochemistry

FV100 is a promising new agent with extreme potency and specificity for varicella-zoster virus (VZV). It is the valyl ester pro-drug of Cf1743, the lead clinical candidate among the highly lipophilic bicyclic nucleoside analogue (BCNA) family discovered in Cardiff/Leuven. Cf1743 is unique amongst antivirals in terms of its structure and lipophilicity. It is exquisitely potent and selective for human VZV. FV100 has recently entered a randomized, controlled Phase II clinical trial for the treatment of shingles, sponsored by Inhibitex.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research